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Abstract Autismspectrumdisorder(ASD)isabehaviourally
defined syndrome where the etiology and pathophysiology is
only partially understood. In a small proportion of children
with the condition, a specific medical disorder is identified,
but the causal significance in many instances is unclear.
Currently, the medical conditions that are best established as
probable causes of ASD include Fragile X syndrome,
Tuberous Sclerosis and abnormalities of chromosome 15
involving the 15q11-13 region. Various other single gene
mutations, genetic syndromes, chromosomal abnormalities
and rare de novo copy number variants have been reported as
beingpossiblyimplicatedinetiology, ashaveseveral anteand
post natal exposures and complications. However, in most
instances the evidence base for an association with ASD is
very limited and largely derives from case reports or findings
from small, highly selected and uncontrolled case series. Not
only therefore, is there uncertainty over whether the condition
is associated, but the potential basis for the association is very
poorly understood. In some cases the medical condition may
be a consequence of autism or simply represent an associated
feature deriving from an underlying shared etiology. Never-
theless, it is clear that in a growing proportion of individuals
potentially causal medical conditions are being identified and
clarification of their role in etio-pathogenesis is necessary.
Indeed, investigations into the causal mechanisms underlying
the association between conditions such as tuberous sclerosis,
Fragile X and chromosome 15 abnormalities are beginning to
cast light on the molecular and neurobiological pathways
involved in the pathophysiology of ASD. It is evident
therefore, that much can be learnt from the study of probably
causal medical disorders as they represent simpler and more
tractable model systems in which to investigate causal
mechanisms. Recent advances in genetics, molecular and
systems biology and neuroscience now mean that there are
unparalleled opportunities to test causal hypotheses and gain
fundamental insights into the nature of autism and its
development.
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Introduction
Ever since it was realized that autism was a result of a
neurodevelopmental abnormality, there have been an
increasing number of reports of various medical conditions
in individuals with autism and autistic-like conditions. For
the most part the early papers comprised case reports and
small case series that described a wide variety of medical
conditions including genetic disorders, chromosomal ab-
normalities and infectious diseases. In addition, various
markers of abnormal brain development (e.g. minor and
major congenital anomalies) and risk factors for brain
damage (e.g. pregnancy and birth complications) were also
described. In general the prevalence of these medical
conditions in individuals with autism was quite low, so it
was often unclear whether they represented a chance co-
occurrence or a true association.
Over the last two decades changes and broadening of our
diagnostic concepts [1–3] and improvements in the methods
of case identification and diagnosis [4, 5] have led to the
notion that autism is a prototypical form of ‘spectrum
disorder’. Autism spectrum disorder (ASD) includes con-
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‘other’ pervasive developmental disorders (ICD-10). The
prevalence of autism spectrum disorder in the UK is now
thought to be in the order of 1% [6].
Parallel developments in medical diagnostics have also
lead to improvements in the detection and diagnosis of
medical conditions, so the prevalence of these conditions in
individuals with ASD has also increased. Table 1 summa-
rises the rates of medical conditions reported in a [7–11]
number of population based studies of individuals with
ASD. It can be anticipated that these prevalence figures will
increase further, as the recent technical advances that have
been made in the identification of submicroscopic chromo-
somal abnormalities (copy number variants [12]) are
applied more routinely in the investigation of children with
autism spectrum disorders. Currently, the evidence indicates
that the conditions are more common in individuals with
mental retardation / intellectual disabilities and those with
atypical autism [13]. The findings raise the possibility of
etiological heterogeneity.
Despite these advances, the aetiological significance of
many medical conditions in individuals with ASD remains
uncertain. Figure 1 outlines the main reasons why a medical
condition may be identified in somebody with an autism
spectrum disorder. Clearly, the first task is to determine
whether the presence of the medical condition is a
coincidental finding, or whether it derives from a true
association. The possibility of chance co-occurrence can
not be dismissed as a theoretical concern that is unlikely to
be relevant. Instead it represents a real possibility for
several reasons. Firstly, individuals with an ASD are more
systematically and intensely investigated for medical con-
ditions than individuals from the general population. Thus,
a condition is more likely to be identified. Moreover, the
true prevalence of the medical disorder in the general
population is often not well specified, as the rarity of many
conditions means that estimation of accurate prevalence
figures would require the investigation of extremely large
sized populations. The challenge is well illustrated by the
difficulty in obtaining accurate estimates of the prevalence
of fragile X in the general population [14]. Taken in
conjunction with the fact that many studies of medical
conditions in ASD are uncontrolled, this is a potentially
important limitation. Second, medical conditions in clinical
populations will be over represented, because individuals
with two or more conditions are more likely to come to
medicalattention—thesocalledBerksonbias[15, 16]. As such,
studies of clinic series really do r e q u i r ed a t af r o mc o m p a r i s o n
clinic populations for the results to be interpretable, unless of
course the effect observed were so large that the null
hypothesis would be implausible. In most examples this is
not the case.
The most unbiased test for association is to undertake an
epidemiologically designed case control study. In this
context it would be best to test a population based sample
of individuals with ASD and an appropriately matched
control population for the medical condition under inves-
tigation. Conversely, it is also valuable to determine the
prevalence of autism spectrum disorder in a population
derived sample of individuals with the specified medical
condition as well as an appropriately selected population
based comparison group. These two sources of information
can then be used to determine the presence and strength of
any association between ASD and the medical condition
Clearly however, the rarity of some of the medical
conditions that are potentially implicated (sometimes less
than 1 in 1000 in the general population and less than 5% in
ASD) as well as the relatively low prevalence of autism
spectrum disorder in the general population means that very
large samples would be required to establish whether a true
association exists. In many cases, the costs of such a study
would be prohibitive. Accordingly, data from carefully
conducted case-control studies of clinic populations may be
the only feasible strategy for initially demonstrating
association.
In any case, the selection of the control group requires
careful consideration. The choice partly depends on the
design and aim of the study. Within the context of
epidemiological studies, an age and sex matched general
population sample would help determine if the two
disorders are associated. In studies of a series of clinic
cases, a decision has to be taken as to what other clinical
population to choose as the comparison group. The choice
primarily lies between a series of cases with another
neuropsychiatric or neurodevelopmental disorder (e.g.
ADHD or mental retardation / intellectual disability) or if
the case series comprises a specific medical condition,
some other medical disorder (e.g. Down syndrome). The
exact choice will depend on the specific question being
addressed. It is noteworthy in this regard that some studies
have compared the frequency of medical condition in series
of cases with autism spectrum disorder to the prevalence in
Table 1 Medical conditions in autism spectrum disorder population
samples
Study Rate
Gillberg & Coleman (1996) 25%
Fombonne et al (1997) 10%
Skjeldal et al (1998) 8%
Barton & Volkmar (1998) 9.8%
Lauritsen et al (2002) 11.9%
Kielinen et al (2004) 12.3%
Oliveira et al (2007) 20%
Total 13.9%
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disability. Sometimes, if no difference in frequency has been
observed, it has been concluded that there is no evidence for
association between the medical condition and autism
spectrum disorder. However, the only formal conclusion
from studies of this kind is that the medical condition is not
specifically associated with ASD, rather than the condition is
not associated with ASD.
Apart from the sampling issues another methodological
consideration concerns the assessment and diagnosis of
autism spectrum disorder. In many studies the established
semi standardised diagnostic tools currently in use were not
available or utilised at the time of the study, so there is
some uncertainty about the validity of diagnoses in some
cases / case series. Moreover, the limited use of any semi
standardised measures means that the details of the patterns
of impairments are not well characterised, so the extent and
degree of homology in symptoms and signs of ASD remain
unknown. The issue is well illustrated in the reports of the
behavioural signs and symptoms founds in individuals with
fetal alcohol syndrome Fetal alcohol [17–21], where
detailed characterisation of the manifestations reveals that
there are different features and profiles of deficits associated
with the medical condition. Clearly therefore, careful
assessment and characterisation is important in order to
determine the degree to which there is specificity in
symptomatology and signs.
Tables 2, 3, 4 and 5 summarises the evidence base for
association between autism spectrum disorder and various
medical conditions, according to the type of study design.
Thelistofdisordersreportedisnotexhaustive,butfocuseson
the conditions where evidence from a combination of sources
Table 2 Medical conditions and autism spectrum disorder
Condition Pop
ASD
Pop
Med
Case-control
ASD
Case control
Med
Case series
ASD
Case series
Med
Case
report
Obstetric complications x x x x x
Congenital Rubella xx
Valproate Embyopathy xx
Neonatal Encephalopathy x x x
Congenital anomalies x x x x x
Ear infection x x x
Malaria x
Herpes simplex xx
Macrocephaly x x x x x
Bowel habit x x x x
Infantile Epilepsy x x x x x x x
Later onset Epilepsy x x x x
Cerebral Malaria x
Thalidomide Embryopathy x
Mechanisms of Association
Medical Condition Autism Spectrum Disorder
Autism Spectrum Disorder
Medical Condition
Shared Aetiology 
Autism Spectrum Disorder
Medical Condition
Autism Spectrum Disorder Aetiology 
Aetiology
Medical Condition
Bias
Fig. 1 Mechanisms of
association
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should refer to Zafeiriou et al. (2007) and Abrahams and
Geschwind (2008) [22, 23].
Even so, most findings still primarily stem from case
reports or small uncontrolled case series, so a good deal of
uncertainty remains as to whether the findings reflect chance
co-occurrences. Where the evidence for association is fairly
clear, the medical condition has been highlighted in the table
in bold. Convincing evidence for an association exists for
tuberoussclerosis[8, 24–29]F r a g i l eX[ 30, 31, abnormalities
in the chromosome 15q11-13 region [32–52], macrocephaly
[53–57] minor congenital anomalies [58–60] and pre- / per-
natal complications [61–74].
Even amongst these examples, the design and method-
ology of the studies entails one or other weakness so the
findings can not be considered indisputably conclusive. In
particular, most studies were not specifically set up to test
for comorbidity between autism spectrum disorder and the
specific medical condition. Rather, the finding comes from
a secondary analysis of the data and the methods of
assessment and diagnosis of the autism spectrum disorder
and / or the medical condition may not have been
conducted as rigorously as would be desirable. Neverthe-
less, in the case of tuberous sclerosis and fragile X
syndrome, it is clear that the evidence base is sufficiently
strong to indicate that a true association is highly likely: the
strength of the association, however, may not have been
accurately estimated.
Having established that a true association likely exists, it
is necessary to consider the possible basis for the
association. The main mechanisms are outlined in Fig. 1.
In most instances, the underlying risk mechanisms or
pathway have not been fully elucidated, but for the purpose
of illustration, some putative pathways can be postulated.
Medical conditions as a consequence of autism spectrum
disorder (ASD)
Atfirstsight,itseemsquiteimprobablethatautismmaybethe
cause of a medical condition, but Ileal lymphoid hyperplasia
serves as a possible example of these mechanisms. Ileal
Table 3 Genetic syndromes
Condition Pop ASD Pop Med Case-control ASD Case control Med Case series ASD Case series Med Case report
Tuberous Sclerosis x x x x x x
Fragile X Full x x x x x
Pre x x x x
Rett syndrome x x x
Smith Lemli Opitz xx
Phenylketonuria xx
Neurofibromatosis 1 x x x x x
Myotonic Dystrophy
DMPK xx
Sotos syndrome
(NSD1) xx
Timothy syndrome x
Cornelia De Lange x
Cohen syndrome x
Condition Pop
ASD
Pop
Med
Case-control
ASD
Case control
Med
Case series
ASD
Case series
Med
Case
report
Neuroligin 4 x x x
Neuroligin 3 x x
Neurexin 1 X x x
CNTNAP2 X x x
PTEN x x
Reelin X x
Shank3 x x x
Table 4 Single gene mutations /
rare variants and autism
spectrum disorder
J Neurodevelop Disord (2009) 1:102–113 105lymphoidhyperplasiahasbeenreportedinsmallcaseseriesof
children with ASD [75]. It is a condition that is also seen in
children with constipation [76]. Children with autism
sometimes have markedly unusual diets because of extreme
food fads. It is therefore quite possible that the abnormal diet
deriving from autistic food fads leads to constipation, which
in turn leads to Ileal lymphoid hyperplasia. The issue
requires investigation.
Medical conditions arising from shared etiology
For some medical conditions, it seems highly likely that
their association with ASD reflects the fact that there is
some underlying shared risk factor that leads to the medical
condition and the ASD. Examples where this mechanism is
likely to underlie the association include macrocephaly,
minor congenital anomalies and later onset epilepsy.
Macrocephaly
A significant minority of children with ASD develop
macrocephaly. [53–57]. In a few individuals with ASD
and macrocephaly, mutations in PTEN and NSD1 have been
identified [77–82]. These mutations give rise to Cowden
and Soto’s syndromes respectively and both conditions are
associated with macrocephaly. Soto’s syndrome has previ-
ously been reported in individuals with ASD [83].
The limited available evidence also suggests that the
macrocephaly seen in cases of ASD is familial [54], raising
the possibility of shared familial liability for macrocephaly
and autism spectrum disorder and the broader autism
phenotype, but this possibility has not yet systematically
examined.
Minor congenital anomalies
Several studies have shown an association between minor
congenital anomalies and ASD [58–60]. The current
evidence indicates that the presence of minor congenital
anomalies indexes a reduced likelihood of familial recurrence
ofASD [84]. Recent findings also indicate that de novo copy
number variants are associated with ASD [85–90]as well as
minor congenital anomalies and mental retardation [91, 92].
Taken together, the findings suggest that the presence of
minor congenital anomalies may index de novo copy
number variants and possibly other non familial risk factors
for ASD.
Epilepsy
Epilepsy occurs in around 20–30% of individuals with
autism and the age of onset tends to be in late childhood or
adolescence [93–97]. The basis for the association is
however poorly understood. There is evidence that the
familial liabilities to epilepsy and autism spectrum disorder
are correlated (at least in the group with onset in later
childhood or beyond), indicating shared familial risks. The
picture may be different however in the group with early
onset epilepsy (see below).
Medical conditions as correlated risk factors
In some instances, the risk pathway may be more complex.
For example, there may be a shared aetiology underlying
the association, but in addition there may be a path
between the medical condition and ASD, modifying or
exacerbating the manifestations of the behavioural syn-
Condition Pop
ASD
Pop
Med
Case-control
ASD
Case control
Med
Case series
ASD
Case series
Med
Case
report
2q37 xx
7q11.3 x x x
15q11-13 x x x x x
15q11.2 x
15q13.3 x
16p11.2 x x x
16p13.1 x x x
17p11.2 x
Trisomy 21 x x x
22q11.2 x x x
22q13.3 x x x
Xp22.3 x x
XXY xx
XO x x x
Table 5 Genomic disorders and
autism spectrum disorder
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[28, 98–103]. In these conditions, the etio-pathogenesis of
the epilepsy is poorly understood, but markers of the presence
of an underlying brain abnormality have been reported to index
an increased risk for ASD. This suggests that there may be a
shared, poorly specified, underlying cause for ASD and
epilepsy. In addition however, there is some evidence to
suggest that epilepsy in this early sensitive period of
development may also be detrimental to brain development
andtheinstantiationofsocialcognitiverepresentations,thereby
predisposing to a risk for ASD or exacerbating the risk
stemming from the underlying brain abnormality [28, 103].
Another example concerns pre and perinatal complica-
tions. A number of studies have reported an association
between ASD and pre and perinatal complications [61–74].
However, the current evidence suggests that these putative
environmental risk factors occurring during pregnancy and
birth may in fact represent a form person-environment
correlation. That is that the genetic factors associated with
ASD lead the individuals to being more likely to experience
certain environmental events. This may apply to the association
with pre and peri - natal problems [71, 104] Nevertheless, it is
possible that these experience sm a ym o d i f yo re x a c e r b a t et h e
manifestations of ASD.
Medical conditions as a cause of ASD
In addition to the better known Mendelian genetic conditions
(e.g. Smith Lemli Opitz [105–107]; Neurofibromatosis 1
[29, 108–113]; Rett syndrome [114–117], there are a
growing number of genomic disorders and single gene
mutations / rare variants that are being identified in
individuals with ASD. These include mutations in Neuro-
ligin 3+4 / neurexin 1 [32, 118–124]; Shank3 [89, 125,
126]; Contactin associated protein-like 2 [127]; Reelin [128]
and PTEN [77, 79]
In addition, ASD has been associated with various micro-
scopic chromosomal abnormalities involving the 15q11-13
region [33–39, 41–47, 49–52, 129–135]; 22q11.2 [136–139]
and submicroscopic de novo copy number variants including
those that involve [85, 88, 90, 140–144] various regions (see
Table 5). Intriguingly, there are a number of reports sug-
gesting that both micodeletions and microduplications may
predispose to ASD at some loci, suggesting that the genes
involved are dosage sensitive and that both up and down
regulation may perturb the pathway underlying the risk for
ASD [145–147].
There are very good reasons to think that when a genetic
condition is confirmed to be associated with ASD, that the
genetic disorder is the cause of the ASD. However, an
important caveat needs to be borne in mind. That is that the
causal factors leading to ASD may also lead to the genetic
condition. Although this is highly unlikely in many cases, the
mechanisms could plausibly underlie the reported association
between genomic disorders (e.g. copy number variants —
CNV’s) and ASD. For example, some factor that leads to ASD
couldalsogiverisetochromosomalinstabilityandapropensity
to develop CNV’s. The current data do not suggest that this is
likely to be the case, but the issue needs further investigation.
Risk pathways
For conditions that are established as being probably causal,
questions arises about the nature of the risk mechanisms
underlying the association. Figure 2 illustrates the potential
risk pathways in schematic form. With recent developments in
network and systems biology, much richer models of causal
pathways have been elaborated [148, 149]. Thus, it is now
appreciated that the genetic risk factors (G1-n)i n t e r a c tw i t ht h e
entire genome to create a disease genome (D1-n), which also
interacts with environmental risk factors (E1-n) to produce
intermediate phenotypes (I1-n) and pathophysiological states
that finally lead to the emergence of disease phenotypes
(P1-n). This model can be applied to complex disorders and
with simplification (reductions in n) to simpler single gene
G1-n = Genetic Risks P1-n = Phenotypes 
D1-n = Disease Genomes I1-n = Intermediate Phenotypes 
E1-n = Environmental Risks
Gn
G2 G1
  En 
  In 
  Dn
 Pn
  Pn
 Pn 
 I2  I1
Fig. 2 Interacting pathogenic networks and pathways
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ation between a medical condition and ASD could derive
from shared genetic risk, overlap in the associated disease
genome, shared environmental risks, overlapping intermediate
phenotypes (i.e. neurobiological and cognitive risks), shared
pathophysiological states and similar or partially overlapping
phenotypic manifestations. The task therefore is to map the
networks of genetic and neurobiological risks leading to ASD
in specific medical conditions and determine how this relates
to the networks and paths identified in the more complex,
‘idiopathic’ form of ASD. It should be noted that for almost
all the known probably causal medical conditions so far
identified, ASD is the outcome in only a subset of cases. For
example, about 50% of individuals with tuberous sclerosis do
not develop an ASD [28, 40] and similarly around 70–80% of
cases of fragile X do not develop an ASD [31]. This means
that studies of individuals with specific medical disorders can
throw light on the risk pathways leading to ASD. Indeed,
mapping the risk mechanisms and paths in simpler and often
rather better understood model systems such as tuberous
sclerosis and fragile X and developing a full model of the risk
and developmental processes involved would be invaluable
for the research field.
Mapping perturbations in gene networks and pathways
Some progress has already been made in clarifying the
nature of the risk processes involved in some of the medical
conditions associated with ASD. For example, it seems that
the risk for ASD in tuberous sclerosis is partly dependent
on whether the TSC1 or TSC2 gene is mutated [150, 151].
There is also some suggestion that the disease genome
expression patterns may be associated with an ASD
outcome in tuberous sclerosis. Likewise, the evidence
indicates that the risk for ASD in fragile X syndrome is
dependent on the presence of the full or pre-mutation [31]
and that the risk for ASD deriving from abnormalities of
chromosome 15 is dependent on the number and parental
origin of the abnormality, with a high risk in individuals
with more copies of the abnormality, especially if these are
maternally derived [43, 134].
To date the most systematic attempt to map disease gene
networks that underlie the risk for ASD has been
undertaken by Nishimura and colleague. They studied gene
expression profiles in lymphoblastoid cell lines established
from individuals with ASD and the fragile X syndrome as
well as individuals with ASD and maternally inherited
interstitial duplication of 15q11-13. They found not only
that there were distinct expression profiles associated with
each genetic condition, but also that there were dysregu-
lated expression profiles that were common to both genetic
condition and that overlapped with the expression profile
seen in cases of idiopathic autism. These investigations
have implicated dysregulation of the Janus Kinase and
Microtubule interacting protein 1 (JAKMIP1) gene and the
G Protein-coupled receptor 155 (GPR155) gene as markers
for autism spectrum disorder [152]. Taken together these
data indicate that dysregulation of specific genes within
networks mark perturbations in the final causal pathway
leading to autism spectrum disorder and the broader
phenotype of autism. Clearly, there remains much more to
be done, but it is evident that the potential exists to use these
approaches to map the dysregulated pathways in detail.
Mapping perturbations in neurobiological networks
Of course, there is a parallel need to map the nature of the
perturbations in the development of neurobiological systems
that underlie the risk for ASD in individuals with associated
medical disorders. Here again, some, albeit limited, progress
has been made in identifying neuroanatomical and neurophys-
iological correlates of outcome. For example, in tuberous
sclerosisthereissomeevidencetosuggestthatthenumberand
location of cortical tubers may index the risk for ASD [28].
Similarly, there are indications that the extent and location of
brain changes in individuals with fragile X syndrome are
associated with the fragile x mental retardation protein levels
and the degree of cognitive impairment and autistic behav-
iour. The research in this area is in its infancy, but there is
clearly much more that can potentially be learnt. Similar
considerations apply to the mapping of putative intermediate
cognitive phenotypes, where some work has also started to
help determine which cognitive processes are key in the
pathway to the behavioural syndrome, but as yet the map is
just beginning to be outlined.
The selection of disorders and focus of investigation
It is evident that different disorders provide different
windows onto the potential risk mechanisms that give rise
to autism spectrum disorder. For example, the study of
genetic conditions that result from mutations in genes
coding for transcription factors (e.g. fragile X) or complex
genomic disorders provide special insights into the nature of
the disease genome associated with ASD. However, because
these conditions are likely to give rise to widespread effects
on the gene networks and because the genetic effects are also
likely to be pleitropic, the extent to which these conditions
can be used to map the neurobiological systems that underlie
ASD is likely to be limited. Other medical condition may be
more informative about the neurobiological basis of the
disorder, so for example investigation of individuals with
neurexin 1, neuroligin 3+4 and Shank 3 mutations would
108 J Neurodevelop Disord (2009) 1:102–113help map the effects of disruptions to synaptic development
and function. Similarly, the stochastic nature of the second
hit events that give rise to the brain abnormalities seen in
tuberous sclerosis mean that this model has special potential
in mapping which brain systems are involved in creating a
risk for ASD and testing theories about whether single or
multiple primary hits in social brain or mirror neuron
networks underlie the risk for ASD. The single deficit
hypothesis postulates that some single underlying neurobio-
logical abnormality may give rise to autism by setting in
motion a cascade of developmental events that ultimately
leads to autism spectrum disorder. The multiple primary
deficit model postulates that ASD is the result of several
separate neurobiological abnormalities (perhaps arising from
the pleitropic effects of genes) each giving rise to specific
components of the cognitive / behavioural phenotype.
Cross disorder comparisons
Further insights may be gained from comparing cases with
different medical conditions according to whether they have
ASD. Comparisons of this kind would help determine
which conditions are necessary and sufficient for the
emergence of ASD. As yet almost no work of this kind
has been undertaken, but opportunity clearly exists and
holds considerable promise.
High risk designs and developmental processes
Medical conditions that are identified and diagnosed early in
infancy can also provides an opportunity to study the
developmental pathways leading to ASD and the sequence
of events that unfold as the developmental cascade pro-
gresses [28, 103, 153]. Insights into these processes may
help identify targets for early therapeutic intervention, both
in individuals with medical conditions that carry a high risk
for ASD as well as in cases at risk for idiopathic ASD.
Testing phenotypic models
Another potential value of investigating individuals with
medical disorders that carry a risk for ASD is to test models
of the architecture of the phenotype and determine the
extent to which the phenotype can be dimensionalized and/
or fractionated. The notion that ASD is not a cohesive,
unitary phenotype has been raised by recent twin study
findings that propose that the phenotype comprises several
dimensions (social, communication, repetitive behaviours)
each with their own genetic underpinnings, as well as
shared genetic risks [154, 155]. The findings from inves-
tigations of individuals with Fragile X syndrome [156–
160], lend support to the notion that the phenotype can be
dimensionalized and that ASD may be at the extreme end
of a quasi normally distributed set of traits, but the extent to
which this also applies to the phenotypic manifestations
seen in other disorder (e.g. tuberous sclerosis) is unclear.
Similarly, it is not know whether the phenotype fractionates
in these conditions and if so what risk factors underlie each
component of the compound phenotype.
Conclusions
An increasing number of medical conditions are being
identified in individuals with ASD and studies are starting
to identify the conditions that probably play a causal role in
etio-pathogenesis. Moreover, it is now appreciated that
rather just representing rare phenomena that should be
excluded from studies of ASD, that research aimed at
understanding why these conditions carry a risk for ASD
can cast light on the key risk processes that lead to ASD.
The investigation of these simpler and potentially more
tractable model systems is in its infancy but it is evident that
it is a fertile area of investigation that can provide important
insights on developmental mechanisms and risk processes.
In addition, the study of these conditions can help answer
current questions about the architecture of the phenotype.
Acknowledgements This research was supported by the UK NIHR
Biomedical Research Centre for Mental Health at the Institute of
Psychiatry, Kings College London and The South London and
Maudsley NHS Foundation Trust’.
References
1. Bailey A, et al. Autism as a strongly genetic disorder: evidence
from a British twin study. Psychol-Med. 1995;25(1):63–77. issn:
0033-2917.
2. Bolton P, et al. A case-control family history study of autism. J
Child Psychol Psychiatry. 1994;35:877–900.
3. Piven J, Palmer P. Psychiatric disorder and the broad autism
phenotype: evidence from a family study of multiple-incidence
autism families. Am J Psychiatry. 1999;156(4):557–63.
4. Lord C, et al. The autism diagnostic observation schedule-
generic: a standard measure of social and communication deficits
associated with the spectrum of autism. J Autism Dev Disord.
2000;30(3):205–23.
5. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-
Revised: a revised version of a diagnostic interview for
caregivers of individuals with possible pervasive developmental
disorders. J Autism Dev Disord. 1994;24(5):659–85.
6. Baird G, et al. Prevalence of disorders of the autism spectrum in a
population cohort of children in South Thames: the Special Needs
and Autism Project (SNAP). Lancet. 2006;368(9531):210–5.
7. Barton M, Volkmar F. How commonly are known medical
conditions associated with autism? J Autism Dev Disord.
1998;28(4):273–8.
J Neurodevelop Disord (2009) 1:102–113 1098. Kielinen M, et al. Associated medical disorders and disabilities
in children with autistic disorder: a population-based study.
Autism. 2004;8(1):49–60.
9. Lauritsen M, et al. Infantile autism and associated autosomal
chromosome abnormalities: a register-based study and a literature
survey. J Child Psychol Psychiatry. 1999;40(3):335–45.
10. Oliveira G, et al. Epidemiology of autism spectrum disorder in
Portugal: prevalence, clinical characterization, and medical
conditions. Dev Med Child Neurol. 2007;49(10):726–33.
11. Sponheim E. Changing criteria of autistic disorders: a comparison
of the ICD-10 research criteria and DSM-IV with DSM-III-R,
CARS, and ABC. J-Autism-Dev-Disord. 1996;26(5):513–25. issn:
0162-3257.
12. Miller DT, Shen Y, Wu BL. Oligonucleotide microarrays for
clinical diagnosis of copy number variation. Curr Protoc Hum
Genet. 2008;Chapter 8: p. Unit 8 12.
13. Rutter M, et al. Autism and known medical conditions: myth and
substance. J Child Psychol Psychiatry. 1994;35:311–22.
14. Hagerman PJ. The fragile X prevalence paradox. J Med Genet.
2008;45(8):498–9.
15. Conn HO, Snyder N, Atterbury CE. The Berkson bias in action.
Yale J Biol Med. 1979;52(1):141–7.
16. Feinstein AR, Walter SD, Horwitz RI. An analysis of Berkson’s
bias in case-control studies. J Chronic Dis. 1986;39(7):495–504.
17. Bishop S, Gahagan S, Lord C. Re-examining the core features of
autism: a comparison of autism spectrum disorder and fetal
alcohol spectrum disorder. J Child Psychol Psychiatry. 2007;48
(11):1111–21.
18. Klug MG, et al. A comparison of the effects of parental risk
markers on pre- and perinatal variables in multiple patient
cohorts with fetal alcohol syndrome, autism, Tourette syndrome,
and sudden infant death syndrome: an enviromic analysis.
Neurotoxicol Teratol. 2003;25(6):707–17.
19. Chakrabarti S, Fombonne E. Pervasive developmental disorders
in preschool children: confirmation of high prevalence. Am J
Psychiatry. 2005;162(6):1133–41.
20. Harris SR, MacKay LL, Osborn JA. Autistic behaviors in
offspring of mothers abusing alcohol and other drugs: a series
of case reports. Alcohol Clin Exp Res. 1995;19(3):660–5. issn:
0145-6008.
21. Nanson JL. Autism in fetal alcohol syndrome: a report of six cases.
Alcohol Clin Exp Res. 1992;16(3):558–65. issn: 0145-6008.
22. Zafeiriou DI, Ververi A, Vargiami E. Childhood autism and
associated comorbidities. Brain Dev. 2007;29(5):257–72.
23. Abrahams BS, Geschwind DH. Advances in autism genetics: on
the threshold of a new neurobiology. Nat Rev Genet. 2008;9
(5):341–55.
24. Curatolo P, Cusmai R. Autism and infantile spasms in children
with tuberous sclerosis [letter]. Dev Med Child Neurol. 1987;29
(4):551.
25. Gillberg IC, Gillberg C, Ahlsen G. Autisic behaviour and
attention deficits in tuberous sclerosis: A population-based study.
Dev Med Child Neurol. 1994;36:50–56.
26. Hunt A, Shepherd C. A prevalence study of autism in tuberous
sclerosis. J Autism Dev Disord. 1993;23:323–39.
27. Smalley S, Tanguay P, Smith M. Association of Autism and
Tuberous Sclerosis. Am J Hum Genet. 1991;49(4):164–164.
28. Bolton PF, et al. Neuro-epileptic determinants of autism
spectrum disorders in tuberous sclerosis complex. Brain.
2002;125(Pt 6):1247–55.
29. Fombonne E, et al. Autism and associated medical disorders in a
French epidemiological survey. J Am Acad Child Adolesc
Psychiatry. 1997;36(11):1561–9.
30. Bailey A, et al. Prevalence of the fragile X anomaly amongst
autistic twins and singletons. J Child Psychol Psychiatry Allied
Discipl. 1993;34(5):673–88.
31. Clifford S, et al. Autism spectrum phenotype in males and
females with fragile X full mutation and premutation. J Autism
Dev Disord. 2007;37(4):738–47.
32. Kim HG, et al. Disruption of neurexin 1 associated with autism
spectrum disorder. Am J Hum Genet. 2008;82(1):199–207.
33. Ouldim K, et al. Tetrasomy 15q11–q13 Diagnosed by FISH in a
Patient with Autistic Disorder. J Biomed Biotechnol. 2007;2007
(3):61538.
34. Dennis NR, et al. Clinical findings in 33 subjects with large
supernumerary marker(15) chromosomes and 3 subjects with
triplication of 15q11–q13. Am J Med Genet. 2006;140(5):434–41.
35. Koochek M, et al. 15q duplication associated with autism in a
multiplex family with a familial cryptic translocation t(14;15)
(q11.2;q13.3) detected using array-CGH. Clin Genet. 2006;69
(2):124–34.
36. Sahoo T, et al. Array-based comparative genomic hybridization
analysis of recurrent chromosome 15q rearrangements. Am J
Med Genet. 2005;139A(2):106–13.
37. Battaglia A. The inv dup(15) or idic(15) syndrome: a clinically
recognisable neurogenetic disorder. Brain Dev. 2005;27(5):365–9.
38. Dykens EM, Sutcliffe JS, Levitt P. Autism and 15q11–q13
disorders: behavioral, genetic, and pathophysiological issues.
Ment Retard Dev Disabil Res Rev. 2004;10(4):284–91.
39. Simic M, Turk J. Autistic spectrum disorder associated with
partial duplication of chromosome 15; three case reports. Eur
Child Adolesc Psychiatry. 2004;13(6):389–93.
40. Bolton PF. Neuroepileptic correlates of autistic symptomatology
in tuberous sclerosis. Ment Retard Dev Disabil Res Rev. 2004;10
(2):126–31.
41. Thomas JA, et al. Genetic and clinical characterization of
patients with an interstitial duplication 15q11–q13, emphasizing
behavioral phenotype and response to treatment. Am J Med
Genet. 2003;119A(2):111–20.
42. Silva AE, et al. Tetrasomy 15q11-q13 identified by fluorescence
in situ hybridization in a patient with autistic disorder. Arq
Neuropsiquiatr. 2002;60(2-A):290–4.
43. Bolton PF, et al. The phenotypic manifestations of interstitial
duplications of proximal 15q with special reference to the autistic
spectrum disorders. Am J Med Genet. 2001;105(8):675–85.
44. Wolpert CM, et al. Three probands with autistic disorder and
isodicentric chromosome 15. Am J Med Genet. 2000;96(3):365–72.
45. Wolpert C, et al. Autistic symptoms among children and young
adults with isodicentric chromosome 15. Am J Med Genet.
2000;96(1):128–9.
46. Rineer S, Finucane B, Simon EW. Autistic symptoms among
children and young adults with isodicentric chromosome 15. Am
J Med Genet. 1998;81(5):428–33.
47. Repetto GM, et al. Interstitial duplications of chromosome region
15q11q13: clinical and molecular characterization. Am J Med
Genet. 1998;79(2):82–9.
48. Sabry MA, Farag TI. Chromosome 15q11–13 region and the
autistic disorder [letter]. J Intellect Disabil Res. 1998;42(Pt 3):259.
49. Schroer RJ, et al. Autism and maternally derived aberrations of
chromosome 15q. Am J Med Genet. 1998;76(4):327–36.
50. Cook EH Jr, et al. Autism or atypical autism in maternally but
not paternally derived proximal 15q duplication. Am J Hum
Genet. 1997;60(4):928–34. issn: 0002-9297.
51. Martinsson T, et al. Maternal origin of inv dup(15) chromosomes
in infantile autism. Eur Child Adolesc Psychiatry. 1996;5(4):185–
92. issn: 1018-8827.
52. Bundey S, et al. Duplication of the 15q11–13 region in a patient
with autism, epilepsy and ataxia. Dev Med Child Neurol.
1994;36(8):736–42.
53. Bolton PF, et al. Association between idiopathic infantile
macrocephaly and autism spectrum disorders. Lancet. 2001;358
(9283):726–7.
110 J Neurodevelop Disord (2009) 1:102–11354. Lainhart JE, et al. Head circumference and height in autism: a
study by the Collaborative Program of Excellence in Autism.
Am J Med Genet. 2006;140(21):2257–74.
55. Woodhouse W, et al. Head circumference in autism and other
pervasive developmental disorders. J Child Psychol Psychiatry.
1996;37(6):665–71.
56. Courchesne E, et al. Mapping early brain development in autism.
Neuron. 2007;56(2):399–413.
57. Redcay E, Courchesne E. When is the brain enlarged in autism?
A meta-analysis of all brain size reports. Biol Psychiatry.
2005;58(1):1–9.
58. Tripi G, et al. Minor physical anomalies in children with autism
spectrum disorder. Early Hum Dev. 2008;84(4):217–23.
59. Walker HA. Incidence of minor physical anomaly in autism. J-
Autism-Child-Schizophr. 1977;7(2):165–76. issn: 0021-9185.
60. Miles JH, et al. Development and validation of a measure of
dysmorphology: useful for autism subgroup classification. Am J
Med Genet. 2008;146A(9):1101–16.
61. Kolevzon A, Gross R, Reichenberg A. Prenatal and perinatal risk
factors for autism: a review and integration of findings. Arch
Pediatr Adolesc Med. 2007;161(4):326–33.
62. Brimacombe M, Ming X, Lamendola M. Prenatal and birth
complications in autism. Matern Child Health J. 2007;11(1):73–9.
63. Maimburg RD, Vaeth M. Perinatal risk factors and infantile
autism. Acta Psychiatr Scand. 2006;114(4):257–64.
64. Stein D, et al. Obstetric complications in individuals diagnosed with
autism and in healthy controls. Compr Psychiatry. 2006;47(1):69–75.
65. Sugie Y, et al. Neonatal factors in infants with Autistic Disorder
and typically developing infants. Autism. 2005;9(5):487–94.
66. Glasson EJ, et al. Perinatal factors and the development of autism:
a population study. Arch Gen Psychiatry. 2004;61(6):618–27.
67. Wilkerson DS, et al. Perinatal complications as predictors of
infantile autism. Int J Neurosci. 2002;112(9):1085–98.
68. Hultman CM, Sparen P, Cnattingius S. Perinatal risk factors for
infantile autism. Epidemiology. 2002;13(4):417–23.
69. Zwaigenbaum L, et al. Pregnancy and birth complications in
autism and liability to the broader autism phenotype. J Am Acad
Child Adolesc Psychiatry. 2002;41(5):572–9.
70. Juul-Dam N, Townsend J, Courchesne E. Prenatal, perinatal, and
neonatal factors in autism, pervasive developmental disorder-not
otherwise specified, and the general population. Pediatrics.
2001;107(4):E63.
71. Bolton PF, et al. Obstetric complications in autism: consequences
or causes of the condition? J-Am-Acad-Child-Adolesc-Psychiatry.
1997;36(2):272–81. issn: 0890-8567.
72. Cryan E, et al. A case-control study of obstetric complications
and later autistic disorder. J-Autism-Dev-Disord. 1996;26
(4):453–60. issn: 0162-3257.
73. Deykin EY, MacMahon B. Pregnancy, delivery, and neonatal
complications among autistic children. Am-J-Dis-Child.
1980;134(9):860–4. issn: 0002-922x.
74. Finegan JA, Quarrington B. Pre-, peri-, and neonatal factors and
infantile autism. J-Child-Psychol-Psychiatry. 1979;20(2):119–28.
issn: 0021-9630.
75. Wakefield AJ, et al. Ileal-lymphoid-nodular hyperplasia, non-
specific colitis, and pervasive developmental disorder in children.
Lancet. 1998;351(9103):637–41.
76. MacDonald TT, Domizio P. Autistic enterocolitis; is it a
histopathological entity? Histopathology. 2007;50(3):371–9.
discussion 380–4.
77. Buxbaum JD, et al. Mutation screening of the PTEN gene in
patients with autism spectrum disorders and macrocephaly. Am J
Med Genet B Neuropsychiatr Genet. 2007;144B(4):484–91.
78. Buxbaum JD, et al. Mutation analysis of the NSD1 gene in
patients with autism spectrum disorders and macrocephaly. BMC
Med Genet. 2007;8:68.
79. Goffin A, et al. PTEN mutation in a family with Cowden
syndrome and autism. Am J Med Genet. 2001;105(6):521–4.
80. Herman GE, et al. Increasing knowledge of PTEN germline
mutations: Two additional patients with autism and macro-
cephaly. Am J Med Genet. 2007;143(6):589–93.
81. Orrico A, et al. Novel PTEN mutations in neurodevelopmental
disorders and macrocephaly. Clin Genet. 2009;75(2):195–8.
82. Varga EA, et al. The prevalence of PTEN mutations in a clinical
pediatric cohort with autism spectrum disorders, developmental
delay, and macrocephaly. Genet Med. 2009;11(2):111–7.
83. Morrow JD, Whitman BY, Accardo PJ. Autistic disorder in Sotos
syndrome: a case report. Eur J Pediatr. 1990;149(8):567–9. issn:
0340-6199.
84. Pickles A, et al. Variable expression of the autism broader
phenotype: findings from extended pedigrees. J Child Psychol
Psychiatry. 2000;41(4):491–502.
85. Christian SL, et al. Novel submicroscopic chromosomal abnor-
malities detected in autism spectrum disorder. Biol Psychiatry.
2008;63(12):1111–7.
86. Hogart A, et al. The comorbidity of autism with the genomic
disorders of chromosome 15q11.2-q13. Neurobiol Dis;2008.
87. Kakinuma H, Sato H. Copy-number variations associated
with autism spectrum disorder. Pharmacogenomics. 2008;9
(8):1143–54.
88. Marshall CR, et al. Structural variation of chromosomes in
autism spectrum disorder. Am J Hum Genet. 2008;82(2):477–88.
89. Moessner R, et al. Contribution of SHANK3 mutations to autism
spectrum disorder. Am J Hum Genet. 2007;81(6):1289–97.
90. Sebat J, et al. Strong association of de novo copy number
mutations with autism. Science. 2007;316(5823):445–9.
91. de Ravel TJ, et al. Molecular karyotyping of patients with MCA/
MR: the blurred boundary between normal and pathogenic
variation. Cytogenet Genome Res. 2006;115(3–4):225–30.
92. Edelmann L, Hirschhorn K. Clinical utility of array CGH for the
detection of chromosomal imbalances associated with mental
retardation and multiple congenital anomalies. Ann N Y Acad
Sci. 2009;1151:157–66.
93. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1
(6):352–8.
94. Howlin P, et al. Adult outcome for children with autism. J Child
Psychol Psychiatry. 2004;45(2):212–29.
95. Amiet C, et al. Epilepsy in autism is associated with intellectual
disability and gender: evidence from a meta-analysis. Biol
Psychiatry. 2008;64(7):577–82.
96. Hara H. Autism and epilepsy: a retrospective follow-up study.
Brain Dev. 2007;29(8):486–90.
97. Canitano R. Epilepsy in autism spectrum disorders. Eur Child
Adolesc Psychiatry. 2007;16(1):61–6.
98. Saemundsen E, Ludvigsson P, Rafnsson V. Autism spectrum
disorders in children with a history of infantile spasms: a
population-based study. J Child Neurol. 2007;22(9):1102–7.
99. Saemundsen E, et al. Autism spectrum disorders in children with
seizures in the first year of life - a population-based study.
Epilepsia. 2007;48(9):1724–30.
100. Deonna T, et al. Autistic regression associated with seizure onset
in an infant with tuberous sclerosis. Dev Med Child Neurol.
2007;49(4):320.
101. Kayaalp L, et al. EEG abnormalities in West syndrome:
correlation with the emergence of autistic features. Brain Dev.
2007;29(6):336–45.
102. Deonna T, Roulet E. Autistic spectrum disorder: evaluating a
possible contributing or causal role of epilepsy. Epilepsia.
2006;47(Suppl 2):79–82.
103. Humphrey A, et al. Autistic regression associated with seizure
onset in an infant with tuberous sclerosis. Dev Med Child
Neurol. 2006;48(7):609–11.
J Neurodevelop Disord (2009) 1:102–113 111104. Deb S, et al. A comparison of obstetric and neonatal complica-
tions between children with autistic disorder and their siblings. J-
Intellect-Disabil-Res. 1997;41(Pt 1):81–6. issn: 0964-2633.
105. Bukelis I, et al. Smith-Lemli-Opitz syndrome and autism
spectrum disorder. Am J Psychiatry. 2007;164(11):1655–61.
106. Tierney E, et al. Abnormalities of cholesterol metabolism in
autism spectrum disorders. Am J Med Genet B Neuropsychiatr
Genet. 2006;141B(6):666–8.
107. Tierney E, et al. Behavior phenotype in the RSH/Smith-Lemli-
Opitz syndrome. Am J Med Genet. 2001;98(2):191–200.
108. Martin I, et al. Transmission disequilibrium study of an
oligodendrocyte and myelin glycoprotein gene allele in 431
families with an autistic proband. Neurosci Res. 2007;59
(4):426–30.
109. Mbarek O, et al. Association study of the NF1 gene and autistic
disorder. Am J Med Genet. 1999;88(6):729–32.
110. Marui T, et al. Association between the neurofibromatosis-1
(NF1) locus and autism in the Japanese population. Am J Med
Genet B Neuropsychiatr Genet. 2004;131B(1):43–7.
111. Williams PG, Hersh JH. Brief report: the association of
neurofibromatosis type 1 and autism. J Autism Dev Disord.
1998;28(6):567–71.
112. Mouridsen SE, et al. Neurofibromatosis in infantile autism and
other types of childhood psychoses. Acta Paedopsychiatr.
1992;55(1):15–8.
113. Gillberg C. Infantile autism and other childhood psychoses in a
Swedish urban region. Epidemiological aspects. J-Child-
Psychol-Psychiatry. 1984;25(1):35–43. issn: 0021-9630.
114. Loat CS, et al. Methyl-CpG-binding protein 2 polymorphisms and
vulnerability to autism. Genes Brain Behav. 2008;7(7):754–60.
115. Matson JL, Dempsey T, Wilkins J. Rett syndrome in adults with
severe intellectual disability: exploration of behavioral character-
istics. Eur Psychiatry. 2008;23(6):460–5.
116. Mount RH, et al. Features of autism in Rett syndrome and severe
mental retardation. J Autism Dev Disord. 2003;33(4):435–42.
117. Mount RH, et al. Towards a behavioral phenotype for Rett
syndrome. Am J Ment Retard. 2003;108(1):1–12.
118. Durand CM, et al. Mutations in the gene encoding the synaptic
scaffolding protein SHANK3 are associated with autism spec-
trum disorders. Nat Genet. 2007;39(1):25–7.
119. Jamain S, et al. Mutations of the X-linked genes encoding
neuroligins NLGN3 and NLGN4 are associated with autism. Nat
Genet. 2003;34(1):27–9.
120. Yan J, et al. Neurexin 1alpha structural variants associated with
autism. Neurosci Lett. 2008;438(3):368–70.
121. Levinson JN, El-Husseini A. A crystal-clear interaction: relating
neuroligin/neurexin complex structure to function at the synapse.
Neuron. 2007;56(6):937–9.
122. Chen X, et al. Structural basis for synaptic adhesion mediated by
neuroligin-neurexin interactions. Nat Struct Mol Biol. 2008;15
(1):50–6.
123. Feng J, et al. High frequency of neurexin 1beta signal peptide
structural variants in patients with autism. Neurosci Lett.
2006;409(1):10–3.
124. Lise MF, El-Husseini A. The neuroligin and neurexin families:
from structure to function at the synapse. Cell Mol Life Sci.
2006;63(16):1833–49.
125. GauthierJ,etal.NoveldenovoSHANK3mutationinautistic patients.
Am J Med Genet B Neuropsychiatr Genet. 2009;150B(3):421–4.
126. Phelan MC. Deletion 22q13.3 syndrome. Orphanet J Rare Dis.
2008;3:14.
127. Bakkaloglu B, et al. Molecular cytogenetic analysis and
resequencing of contactin associated protein-like 2 in autism
spectrum disorders. Am J Hum Genet. 2008;82(1):165–73.
128. Bonora E, et al. Analysis of reelin as a candidate gene for autism.
Mol Psychiatry. 2003;8(10):885–92.
129. Kato C, et al. Association study of the 15q11–q13 maternal
expression domain in Japanese autistic patients. Am J Med
Genet B Neuropsychiatr Genet. 2008;147B(7):1008–12.
130. Weiss LA, et al. Association between microdeletion and micro-
duplication at 16p11.2 and autism. N Engl J Med. 2008;358
(7):667–75.
131. Bolton PF, et al. Chromosome 15q11–13 abnormalities and other
medical conditions in individuals with autism spectrum disor-
ders. Psychiatr Genet. 2004;14(3):131–7.
132. Sabry MA, Farag TI. Chromosome 15q11-13 region and the
autistic disorder. J Intellect Disabil Res. 1998;42(Pt 3):259.
133. Veltman MW, et al. Prader-Willi syndrome–a study comparing
deletion and uniparental disomy cases with reference to autism
spectrumdisorders.Eur ChildAdolescPsychiatry.2004;13(1):42–50.
134. Milner KM, et al. Prader-Willi syndrome: intellectual abilities
and behavioural features by genetic subtype. J Child Psychol
Psychiatry. 2005;46(10):1089–96.
135. Sahoo T, et al. Microarray based comparative genomic hybrid-
ization testing in deletion bearing patients with Angelman
syndrome: genotype-phenotype correlations. J Med Genet.
2006;43(6):512–6.
136. Kates WR, et al. Comparing phenotypes in patients with
idiopathic autism to patients with velocardiofacial syndrome
(22q11 DS) with and without autism. Am J Med Genet.
2007;143A(22):2642–50.
137. Mukaddes NM, Herguner S. Autistic disorder and 22q11.2
duplication. World J Biol Psychiatry. 2007;8(2):127–30.
138. Antshel KM, et al. Autistic spectrum disorders in velo-cardio
facial syndrome (22q11.2 deletion). J Autism Dev Disord.
2007;37(9):1776–86.
139. Vorstman JA, et al. The 22q11.2 deletion in children: high rate of
autistic disorders and early onset of psychotic symptoms. J Am
Acad Child Adolesc Psychiatry. 2006;45(9):1104–13.
140. Bremer A, et al. Screening for copy number alterations in loci
associated with autism spectrum disorders by two-color multi-
plex ligation-dependent probe amplification. Am J Med Genet B
Neuropsychiatr Genet.2009.
141. CuscoI,etal.Autism-specificcopynumbervariantsfurtherimplicate
the phosphatidylinositol signaling pathway and the glutamatergic
synapse in the etiology of the disorder. Hum Mol Genet. 2009.
142. Szatmari P, et al. Mapping autism risk loci using genetic linkage
and chromosomal rearrangements. Nat Genet. 2007;39(3):319–28.
143. Stefansson H, et al. Large recurrent microdeletions associated
with schizophrenia. Nature. 2008;455(7210):232–6.
144. Roohi J, et al. Disruption of contactin 4 in three subjects with
autism spectrum disorder. J Med Genet. 2009;46(3):176–82.
145. Van der Aa N, et al. Fourteen new cases contribute to the
characterization of the 7q11.23 microduplication syndrome. Eur
J Med Genet. 2009;52(2–3):94–100.
146. Potocki L, et al. Characterization of Potocki-Lupski syndrome
(dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive
critical interval that can convey an autism phenotype. Am J
Hum Genet. 2007;80(4):633–49.
147. Samaco RC, et al. A partial loss of function allele of methyl-
CpG-binding protein 2 predicts a human neurodevelopmental
syndrome. Hum Mol Genet. 2008;17(12):1718–27.
148. Loscalzo J, Kohane I, Barabasi AL. Human disease classification
in the postgenomic era: a complex systems approach to human
pathobiology. Mol Syst Biol. 2007;3:124.
149. Goh KI, et al. The human disease network. Proc Natl Acad Sci U
S A. 2007;104(21):8685–90.
150. Lewis JC, et al. Genotype and psychological phenotype in
tuberous sclerosis. J Med Genet. 2004;41(3):203–7.
151. Barrett S, et al. An autosomal genomic screen for autism.
Collaborative linkage study of autism. Am J Med Genet.
1999;88(6):609–15.
112 J Neurodevelop Disord (2009) 1:102–113152. Nishimura Y, et al. Genome-wide expression profiling of
lymphoblastoid cell lines distinguishes different forms of autism
and reveals shared pathways. Hum Mol Genet. 2007;16
(14):1682–98.
153. Humphrey A, et al. A prospective longitudinal study of early
cognitive development in tuberous sclerosis-a clinic based study.
Eur Child Adolesc Psychiatry. 2004;13(3):159–65.
154. Ronald A, et al. Genetic heterogeneity between the three
components of the autism spectrum: a twin study. J Am Acad
Child Adolesc Psychiatry. 2006;45(6):691–9.
155. Ronald A, Happe F, Plomin R. The genetic relationship between
individual differences in social and nonsocial behaviours
characteristic of autism. Dev Sci. 2005;8(5):444–58.
156. Dissanayake C, et al. Behavioural and cognitive phenotypes in
idiopathic autism versus autism associated with fragile X
syndrome. J Child Psychol Psychiatry. 2009;50(3):290–9.
157. Harris SW, et al. Autism profiles of males with fragile X
syndrome. Am J Ment Retard. 2008;113(6):427–38.
158. Loesch DZ, et al. Molecular and cognitive predictors of the
continuum of autistic behaviours in fragile X. Neurosci Biobehav
Rev. 2007;31(3):315–26.
159. Muller RA. The study of autism as a distributed disorder. Ment
Retard Dev Disabil Res Rev. 2007;13(1):85–95.
160. Roberts JE, et al. Social approach and autistic behavior in
children with fragile X syndrome. J Autism Dev Disord. 2007;37
(9):1748–60.
J Neurodevelop Disord (2009) 1:102–113 113